Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated proteins. The glycosylated proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.

Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated proteins. The glycosylated proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.

Disclosed is a pharmaceutical composition or food composition for the treatment or prevention of hypertension, containing a peptide isolated from a fraction of a flounder surimi hydrolysate as an active ingredient and is based on the finding that the flounder surimi has an effect of reducing blood pressure, and the hydrolysate of the flounder surimi, the fraction of the hydrolysate of the flounder surimi and peptides isolated from the fraction of the hydrolysate of the flounder surimi have an inhibition activity against an angiotensin I converting enzyme (ACE). Thus, peptides isolated from the fraction of the hydrolysate of the flounder surimi can be used for pharmaceutical compositions or food compositions for treating or preventing hypertension. Also, the present invention is based on the finding that the hydrolysate of the flounder surimi and peptides isolated therefrom have radical scavenging effect and a protective effect against oxidative stress and are thus capable of inhibiting ROS production, lipid peroxidation and apoptosis. Accordingly, peptides isolated from fractions of the hydrolysate of the flounder surimi can be used for food compositions for antioxidation.

Disclosed is a pharmaceutical composition or food composition for the treatment or prevention of hypertension, containing a peptide isolated from a fraction of a flounder surimi hydrolysate as an active ingredient and is based on the finding that the flounder surimi has an effect of reducing blood pressure, and the hydrolysate of the flounder surimi, the fraction of the hydrolysate of the flounder surimi and peptides isolated from the fraction of the hydrolysate of the flounder surimi have an inhibition activity against an angiotensin I converting enzyme (ACE). Thus, peptides isolated from the fraction of the hydrolysate of the flounder surimi can be used for pharmaceutical compositions or food compositions for treating or preventing hypertension. Also, the present invention is based on the finding that the hydrolysate of the flounder surimi and peptides isolated therefrom have radical scavenging effect and a protective effect against oxidative stress and are thus capable of inhibiting ROS production, lipid peroxidation and apoptosis. Accordingly, peptides isolated from fractions of the hydrolysate of the flounder surimi can be used for food compositions for antioxidation.

A fusion tag according to an embodiment of the present invention may increase the water solubility and expression level of a target protein. As the water solubility and expression level of a target protein in host cell can be increased by a recombinant vector including the fusion tag, the fusion tag can be advantageously used in industry.

The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (uPA), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator in a variety of therapeutic, diagnostic and prophylactic indications.

The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (uPA), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator in a variety of therapeutic, diagnostic and prophylactic indications.

The present invention relates to polypeptides, compositions and methods for preventing and/or treating skin conditions including dermal aging and skin conditions associated with UV exposure.

A material for endobronchial occlusion capable of repairing or replacing tissue is disclosed. The material contains a protein (A), wherein the protein (A) contains at least one of a polypeptide chain (Y) or a polypeptide chain (Y′), a total number of the polypeptide chain (Y) and the polypeptide chain (Y′) in the protein (A) is 1 to 100, the polypeptide chain (Y) is a polypeptide chain consisting of 2 to 200 tandem repeats of at least one amino acid sequence (X) among an amino acid sequence VPGVG, an amino acid sequence GVGVP 4, GPP, GAP, and an amino acid sequence GAHGPAGPK, the polypeptide chain (Y′) is a polypeptide chain in which each of a total of 5% or less of amino acids in the polypeptide chain (Y) is replaced by at least one of a lysine residue or an arginine residue, with a total number of the lysine and arginine residues being 1 to 100.

A material for endobronchial occlusion capable of repairing or replacing tissue is disclosed. The material contains a protein (A), wherein the protein (A) contains at least one of a polypeptide chain (Y) or a polypeptide chain (Y′), a total number of the polypeptide chain (Y) and the polypeptide chain (Y′) in the protein (A) is 1 to 100, the polypeptide chain (Y) is a polypeptide chain consisting of 2 to 200 tandem repeats of at least one amino acid sequence (X) among an amino acid sequence VPGVG, an amino acid sequence GVGVP 4, GPP, GAP, and an amino acid sequence GAHGPAGPK, the polypeptide chain (Y′) is a polypeptide chain in which each of a total of 5% or less of amino acids in the polypeptide chain (Y) is replaced by at least one of a lysine residue or an arginine residue, with a total number of the lysine and arginine residues being 1 to 100.